Showing 2061-2070 of 5909 results for "".
- ASCRS Introduces Richard L. Lindstrom Lecture for 2021 Annual Meetinghttps://modernod.com/news/ascrs-introduces-richard-l-lindstrom-lecture-for-2021-annual-meeting/2478960/The American Society of Cataract and Refractive Surgery (ASCRS) has announced the inaugural Richard L. Lindstrom Lecture and Medal, which will be delivered along with other distinguished lectures at the 2021 ASCRS Annual Meeting in Las Vegas, Nevada. The Richard L. Lindstrom Lecture and Me
- Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-36-million-series-a-financing-to-advance-development-of-novel-presbyopia-correcting-eye-drop/2478952/Visus Therapeutics announced the close of a $36 million Series A Preferred Stock financing to advance the clinical development program for the company’s lead asset, Brimochol, an investigational drug designed to be a
- Researchers Develop New Noninvasive Technique to Image Human Eyehttps://modernod.com/news/researchers-develop-new-noninvasive-technique-to-image-human-eye/2478947/Researchers have developed a noninvasive technique that can capture images of rod and cone photoreceptors with unprecedented detail. The advance could lead to new treatments and earlier detection for retinal diseases such as macular degeneration, according to a National Eye Institute news release
- Retinal Therapeutics Development Company Oxular Completes $37 Million (£27 million) Financinghttps://modernod.com/news/retinal-therapeutics-development-company-oxular-completes-37-million-27-million-financing/2478922/Oxular announced that it has completed a $37 million (£27 million) to fund planned further clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME), as well as accelerating development of its early-product pipeline. The financing was led by Forbion
- Researchers Use Patients’ Cells to Test Gene Therapy for a Form of Leber Congenital Amauroshttps://modernod.com/news/researchers-use-patients-cells-to-test-gene-therapy-for-a-form-of-leber-congenital-amauros/2478810/Scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy for a rare disease that causes severe vision loss in childhood. A form of Leber congenital amaurosis, the disease is caused by autosomal-dominant mutations in the CRX gene, which are ch
- Zenni Releases New Anti-Fog Glasses Lenses to Address Mask-Related Fogginghttps://modernod.com/news/zenni-releases-new-anti-fog-glasses-lenses-to-address-mask-related-fogging/2478797/Zenni announced a 2-in-1 anti-fog + anti-reflective lens solution to solve a pain point for glasses wearers during the pandemic. Developed in 2020 as a response to the pervasive consumer issue of glasses fogging up while wearing face coverings, these new anti-fog coated lenses are the only low pr
- Alcon Launches Precision1 for Astigmatism Contact Lenses in the UShttps://modernod.com/news/alcon-launches-precision1-for-astigmatism-contact-lenses-in-the-us/2478780/Alcon announced the US launch of Precision1 for Astigmatism, a daily disposable, silicone hydrogel (SiHy) contact lens designed for astigmatic patients. “Precision1, with its cutting-edge Smartsurface technology, has become the fastest-growing daily disposable contact lens brand in the U.S
- Smart Contact Lens Targets Vision Improvement for Those With Impairmentshttps://modernod.com/news/smart-contact-lens-targets-vision-improvement-for-those-with-impairments/2478766/A contact lens that operates like a smartphone in the eye was the breakout but not-yet-ready-for-prime-time health tech at Consumer Electronics Show (CES) this year, according to a Medscape report. The device wields computing and imaging p
- Ocugen and Bharat Biotech to Co-Develop COVID-19 Vaccine for the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-to-co-develop-covaxin-covid-19-vaccine-for-the-us-market/2478692/Ophthalmic biopharma company Ocugen has signed a letter of intent to co-develop Bharat Biotech’s COVID-19 vaccine candidate, Covaxin, an advanced stage whole-viron inactivated vaccine candidate, for the United States market. Covaxin has been evaluated in approximately 1,000 subjects in pha
- Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseaseshttps://modernod.com/news/gyroscope-therapeutics-and-the-university-of-pennsylvania-announce-research-agreement-to-develop-gene-therapies-for-serious-eye-diseases/2478679/Gyroscope Therapeutics announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope